Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patent Reform Bill In House Limits “Inequitable Conduct” Defense

Executive Summary

Amended patent reform legislation that cleared the House Judiciary Committee July 18 responds to innovator drug industry concerns by limiting the circumstances in which the inequitable conduct defense may be used in patent challenges
Advertisement

Related Content

Patent Reform: Brands Get Damages, Generics Have Inequitable Conduct
Patent Reform: Brands Get Damages, Generics Have Inequitable Conduct
Patent Reform Legislation Introduced; Damages, Inequitable Conduct In Flux
Patent Reform Legislation Introduced; Damages, Inequitable Conduct In Flux
Patent Reform Face-Off Turns To Face Time For Pharma And Tech Companies
Patent Reform Face-Off Turns To Face Time For Pharma And Tech Companies
Patent Reform Bill Clears House; BIO Opposes Provision on Damages Awards
Patent Reform Bill Clears House; BIO Opposes Provision on Damages Awards
Patent Reform Bills Clear House And Senate Judiciary Committees
Patent Reform Bills Clear House And Senate Judiciary Committees
Advertisement
UsernamePublicRestriction

Register

PS048629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel